Dr. Michael Williams, LRF Scientific Advisory Board member and former Chair of the Mantle Cell Lymphoma Consortium, discusses current treatment options for mantle cell lymphoma and what is on the horizon. Learn more about what research is being done, potential new targeted therapies, clinical trials and his involvement with the LRF. Learn more...
Welcome to Focus on MCL
The FocusOnMCL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by mantle cell lymphoma (MCL).
We invite you to browse the site to learn more about MCL.
Getting the Facts
Mantle cell lymphoma is a rare form of non-Hodgkin lymphoma (NHL), constituting only six percent of all NHL cases in the United States. It is considered an aggressive B-cell lymphoma and gets its name because mantle cell tumors are composed of cells that come from the “mantle zone” of the lymph node.
Recent Research
Recent research into mantle cell lymphoma has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for MCL patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.
Ask the Doctor
LRF's Ask the Doctor About Lymphoma program is a national series of community based-programs which provide updates on lymphoma and new treatment options for patients.
YouTube
Subscribe to LRF’s YouTube Channel for videos on lymphoma, treatment options, and clinical trials. Gain access to in-depth videos with leading lymphoma experts.
Twitter Feed @lymphoma
- @FDA_Drug_Info moved to increased 2 needed cancer drugs and issued a draft guidance on drug shortage problems @latimes t.co/o7cweY6j
- Story about 2 women, Kimi-Kali and Julie, who formed an unbreakable bond while both fighting non-Hodgkin Lymphoma. t.co/5ehpuRZD
- Dr. Michael Williams talks about the latest research and treatment options for Mantle Cell Lymphoma (MCL) t.co/pB9ECmEF #focusonmcl









